The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma

Sorafenib, a multikinase inhibitor targeting the Ras/Raf/MAPK (mitogen-activated protein kinase) and vascular endothelial growth factor signaling pathways is an established treatment option for patients with advanced-stage hepatocellular carcinoma (HCC); however, despite its clinical benefit, chemor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Liangtao, Mayerle, Julia, Ziesch, Andreas, Reiter, Florian P., Gerbes, Alexander L., De Toni, Enrico N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450909/
https://www.ncbi.nlm.nih.gov/pubmed/30962952
http://dx.doi.org/10.1038/s41420-019-0165-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450909/
https://www.ncbi.nlm.nih.gov/pubmed/30962952
http://dx.doi.org/10.1038/s41420-019-0165-7

Ejemplares similares